Building a Career in Cell and Gene Therapy: From Bench to Patient

Every prime-editing trial and CAR-T case report sits on top of a workforce that is, frankly, not big enough yet. The cell and gene therapy (CGT) sector keeps adding programs faster than universities can produce the people to run them. The result in 2026 is a hiring market with genuine openings across multiple job tracks — most of which the average applicant doesn''t know exist.

This piece walks through the full role spectrum, the skill stack each one demands, the realistic education pathways, and where to apply. It also flags the under-the-radar tracks where applicants are scarcer than at the obvious research roles.

The role spectrum most applicants miss

When most undergraduates think ''CGT career'' they think bench scientist. That''s one role of at least six. The full picture:

• Research scientist. Discovers and characterises new editing tools, viral vectors, or cell-engineering strategies. Mostly PhD-required.
• Process development (PD). Translates a working benchtop process into something that can be reproduced at scale. The bridge between research and manufacturing. MSc-friendly.
• GMP manufacturing. Runs the actual production of clinical-grade cell or gene therapy product. BSc-friendly; the largest single category of unfilled CGT roles in 2026.
• Quality control / quality assurance. Tests product against release specs and audits processes against regulatory requirements. BSc + GMP experience.
• Clinical operations. Coordinates the running of CGT clinical trials, which look meaningfully different from small-molecule trials. BSc + clinical training.
• Regulatory affairs. Translates the science into IND/BLA submissions and ongoing FDA / EMA correspondence. Often BSc/MSc, sometimes JD with science background.

The core technical skill stack

Almost every entry into a CGT role goes through some combination of these techniques. Build evidence of two or three before applying.

• Mammalian cell culture. Aseptic technique, primary T-cell or HSC isolation, expansion protocols. Non-negotiable.
• Flow cytometry / FACS. Multiparameter panels, gating logic, sort recovery. The lingua franca of cell therapy.
• Viral vector production and titration. Lentivirus, AAV, retrovirus — different vectors for different therapies.
• CRISPR design and validation. Guide design, off-target analysis, base/prime editor selection.
• qPCR and ddPCR. Copy-number determination, residual DNA testing.
• LIMS and electronic batch records. Increasingly expected even at the research interface.

Education pathways

The right credential depends on where in the value chain you want to sit.

• BSc in molecular biology, biochemistry, biomedical engineering, or pharmacology. Sufficient for entry-level manufacturing, QC, and research associate roles. Pair with an undergraduate research project that includes cell culture and at least one ''omics'' technique.
• MSc in regenerative medicine, gene therapy, or biotechnology. Opens process development, mid-level research, and clinical operations roles. Several universities now run dedicated CGT MSc programs (UCL, USC, Penn).
• PhD in molecular biology, immunology, or related. Required for senior scientist and group leader trajectories. Choose labs that publish in Nature Biotech, Mol Therapy, or Cell Stem Cell.
• MD or MD-PhD. Required for clinical investigator and chief medical officer trajectories.

Named companies hiring in 2026

The big-name CGT employers all run intern, co-op, or early-career programs: CRISPR Therapeutics, Vertex Pharmaceuticals, Beam Therapeutics, Prime Medicine, Editas Medicine, Sangamo, Intellia, bluebird bio. The CAR-T side: Bristol Myers Squibb (Juno/Celgene), Gilead (Kite), Novartis, Legend Biotech, Arcellx. Cell-therapy CDMOs that hire heavily at the manufacturing level: Lonza Cell & Gene, ElevateBio, Catalent CGT. Geographic concentration is high: Cambridge MA, the SF Bay Area, Research Triangle Park, and London/Cambridge UK account for most of the role density.

How to actually land the first role

• Get one summer of cell-culture experience as an undergrad. Document it concretely on your résumé — the protocols you ran, not vague ''lab experience''.
• Take an extension course in GMP, biomanufacturing, or regulatory affairs. Stanford, ISPE, and BioPharma Institute offer them. Cheap signal.
• Apply to internships at the CGT CDMOs even more than at the brand-name biotechs. The pipeline-to-hire ratio is dramatically better.
• Build a small portfolio: a written walkthrough of a CGT product''s clinical-trial design, an annotated viral-vector protocol, a critique of a recent paper. Recruiters read these.

Honest caveats

The CGT sector is cyclical. A negative Phase 3 readout for one program can ripple through dozens of related companies — Kite''s 2017–2018 layoffs and the 2023 mid-cap biotech contraction both illustrate the pattern. Geographic concentration also means most roles require relocation. And the salary curve is steep but stretched: entry-level pay is competitive with general biotech, but six-figure roles typically require 4–6 years of experience or an advanced degree.